News Release

ZymoGenetics to Host Conference Call and Webcast on February 11, 2010 to Discuss 2009 Year-end Financial Results

February 4, 2010

SEATTLE, Feb 04, 2010 (BUSINESS WIRE) -- ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that it will report fourth quarter and year-end 2009 financial results on Thursday, February 11, 2010 after market close. Following the announcement, members of the company's senior management will discuss the results and provide a corporate update.

Conference Call and Webcast Information

ZymoGenetics Fourth Quarter and Year-End 2009 Financial Results Conference Call will be held on February 11, 2010 at 4:30 p.m. Eastern Time and may be accessed at http://www.zymogenetics.com or by dialing 877-407-0778 (International: 201-689-8565). Participants should dial in to the call approximately 10 minutes prior to the scheduled start time to register. A live audio webcast and slide presentation can be accessed by going to: http://www.zymogenetics.com. The webcast will be archived for 60 days.

For replay, please visit http://www.zymogenetics.com or use the following information:

• U.S. callers: 877-660-6853
• International callers: 201-612-7415

Replay passcode account #: 286

Conference ID #: 344114

About ZymoGenetics

ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. In the past, ZymoGenetics has conducted extensive discovery research to identify potential product candidates, with a primary focus in autoimmune disorders and oncology. After a series of strategic initiatives undertaken in 2008 and 2009, ZymoGenetics is now focused on developing and commercializing a limited number of product candidates, which it believes have substantial medical and commercial potential. ZymoGenetics has developed and is marketing RECOTHROM(R) Thrombin, topical (Recombinant) in the United States. ZymoGenetics has two product candidates in clinical development: PEG-Interferon lambda, being studied in collaboration with Bristol Myers Squibb (BMS) for treatment of hepatitis C virus (HCV) infection, and IL-21, being tested by us as a potential treatment for metastatic melanoma. In addition, ZymoGenetics has an anti-IL-31 monoclonal antibody in preclinical development, which it expects to test initially as a treatment for atopic dermatitis. Several of the product candidates previously identified through ZymoGenetics' discovery research efforts have been licensed to and are being developed by third parties, including Merck Serono and Novo Nordisk. ZymoGenetics is eligible to receive milestone payments and royalties related to these assets. For further information, visit www.zymogenetics.com.

SOURCE: ZymoGenetics, Inc.

ZymoGenetics, Inc.
Susan W. Specht, 206-442-6592